Viewing Study NCT03266692

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 3:41 PM
Ignite Modification Date: 2026-06-16 @ 2:28 AM
Study NCT ID: NCT03266692
Status: TERMINATED
Last Update Posted: 2020-03-30
First Post: 2017-08-22
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma
Sponsor: Cogent Biosciences, Inc.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Multiple Myeloma View
None Multiple Myeloma in Relapse View
None Refractory Multiple Myeloma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None BCMA View
None SEA-BCMA View
None B Cell Maturation Antigen View
None ACTR View
None ACTR087 View
None T cell View
None T cell product View
None relapsed View
None refractory View
None multiple myeloma View
None adoptive T cells View
None autologous View
None gene therapy View
None cell therapy View